Related Experiment Video
Updated: Jan 13, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
Hypertension in Diabetes: Numbers or Outcomes?
Theocharis Koufakis1, Michael Doumas2
1Second Propaedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 49 Konstantinoupoleos Str., 54642, Thessaloníki, Greece. thkoyfak@auth.gr.
Insights
Managing hypertension in diabetes is complex, requiring more than just blood pressure targets. Combination therapies targeting multiple issues improve outcomes for patients with both conditions.
Area of Science:
- Cardiology
- Endocrinology
- Nephrology
Background:
- Hypertension is a frequent and serious comorbidity in diabetes patients.
- The dual condition significantly increases cardiovascular and renal complications.
- Complex pathophysiology involves insulin resistance, endothelial dysfunction, and renin-angiotensin-aldosterone system (RAAS) activation.
Purpose of the Study:
- To discuss the complexities of managing hypertension in diabetes.
- To evaluate the role of specific therapies and combination therapy.
- To argue for outcome-based assessment of treatment success.
Main Methods:
- Review of epidemiological evidence on hypertension in diabetes.
- Discussion of pathophysiological interactions.
- Analysis of therapeutic strategies including RAAS inhibitors and SGLT2 inhibitors.
Main Results:
- High prevalence and burden of complications in dual condition.
- RAAS inhibitors and SGLT2 inhibitors show benefits beyond BP reduction.
- Combination therapy offers a rationale for targeting multiple abnormalities.
Conclusions:
- Hypertension management in diabetes is multifactorial and challenging.
- Treatment success should be evaluated by prognostic outcomes, not solely BP values.
- Combination therapies are rational for addressing complex pathophysiology.
Abstract:
Hypertension is one of the most frequent and consequential comorbidities in people with diabetes, yet its management remains less straightforward than guideline tables might suggest. Epidemiological evidence confirms the high prevalence and the disproportionate burden of cardiovascular and renal complications in this dual condition. The pathophysiology is complex: insulin resistance, endothelial dysfunction, and activation of the renin-angiotensin-aldosterone system (RAAS) interact, often with cumulative effects. Most recommendations endorse a blood pressure (BP) target below 130/80 mmHg, but whether strict numerical thresholds should dominate practice remains debated. Therapies such as RAAS inhibitors and sodium-glucose cotransporter-2 inhibitors demonstrate consistent benefits, extending beyond BP reductions. Given this multifactorial background, combination therapy carries a strong rationale, as it allows simultaneous targeting of multiple pathophysiological abnormalities. This article argues that success should be judged not only by BP values but by the outcomes that alter prognosis.
More Related Videos
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Hypertension V: Nursing Management
Hypertension I: Introduction
Hypertension III: Clinical Manifestations and Diagnostic Studies
Diabetes: Symptoms, Diagnosis, and Complications
Hypertension and Regulation of Blood Pressure

